NEUROONE MEDICAL TECHNOLOGIES Corp — Form 8-K
Filed October 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
NeuroOne reported preliminary FY2026 product revenue of $10.5M (15.6% YoY growth, at top of guidance), with Q4 revenue of $3.8M (38.4% YoY growth). In September 2026, the company secured a record $4.5M purchase order—its largest ever—with ~$1.0M shipped in September and $3.6M expected to ship in Q1–Q2 FY2027. Total open purchase orders reached $5.4M as of September 30, 2026.
Why this rating
Record $4.5M order is 17.6% of company market cap; $5.4M backlog provides visibility. Strong revenue growth and largest order in company history are material catalysts for a $25.5M-cap company.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.23 ▼ 1.00% | at our read · unknown $1.24 | +10 min · unknown $1.35 ▲ 8.79% | +30 min · unknown $1.25 ▲ 0.40% | +1 hr · unknown $1.19 ▼ 4.03% | +4 hrs pending |
The stock had already moved +1.01% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.